PACT Pharma is synthesizing neo-epitope targeted T cells and producing a personalized adoptive cell therapy designed to benefit each cancer patient.
PACT Pharma is dedicated to synthesizing a tsunami of neo-epitope targeted T cells and producing a personalized adoptive cell therapy designed to benefit each individual cancer patient.
The technology in development at PACT Pharma aims to reprogram immune systems to target and eradicate the cancer. PACT Pharma is engineering synthetic tumor-infiltrating lymphocytes (synthetic TILs), tailored for each patient's cancer with highly efficient turnaround in manufacturing from tumor biopsy to re-infusion of autologous synthetic TILs back into the patient.
PACT Pharma raised $95 million in Series B financing. Alphabet Inc.'s venture arm GV led the round, with participation from Invus Group, Canaan Partners, Casdin Capital, Wu Capital and other undisclosed investors.